Almost 3,000 Patients Treated Under UK’s Early Access To Medicines Scheme
Data provided to the Pink Sheet under freedom of information requests show the scale of patient access that has been delivered under the UK’s scheme for early access to products that have yet to receive a marketing authorization.
You may also be interested in...
Eli Lilly’s new type 2 diabetes injectable treatment Mounjaro is the latest GLP-1 to secure reimbursement in England following a positive opinion from HTA body NICE. Roche’s lymphoma drug Columvi and a new indication for UCB’s Bimzelx were also backed in recent draft guidance.
With the clock ticking on UK drug pricing negotiations, it is still unclear whether even high-level terms of a new voluntary deal will be agreed in time.
The pharmaceutical industry says financial uncertainties are a key reason why the English Innovative Medicines Fund (IMF) – offering the potential for time-limited funding for promising non-cancer treatments where benefits are uncertain at launch - has still not been used a year after it was put in place. Industry wants the National Health Service to share the financial risk of taking part in the fund.